CYP1A2 Gene Polymorphism and Theophylline Level in Asthma by Lorensia, Amelia et al.
 
 
 
   
  
63
DOI: 10.18585/inabj.v11i1.475 CYP1A2 Polymorphism and Theophylline Level in Asthma (Lorensia A, et al.)Indones Biomed J. 2019; 11(1): 63-9R E S E A R C H  A R T I C L E
CYP1A2 Gene Polymorphism and Theophylline Level in Asthma
Amelia Lorensia1,, Zullies Ikawati2, Tri Murti Andayani2, Daniel Maranatha3, Mariana Wahyudi4
1Department of Clinical Pharmacy-Community, Faculty of Pharmacy, Universitas Surabaya, Jl. Raya Kalirungkut, Surabaya, Indonesia
2Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Jl. Farmako Sekip Utara, Yogyakarta, Indonesia
3Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Airlangga/General Hospital Dr. Soetomo, 
Jl. Mayjen Prof. Dr. Moestopo No.47, Surabaya, Indonesia
4Department of Purification and Molecular Biology, Faculty of Biotechnology, Universitas Surabaya, Jl. Raya Kalirungkut, Surabaya, Indonesia
Corresponding author. E-mail: amelia.lorensia@staff.ubaya.ac.id
Received date: Jun 11, 2018; Revised date: Oct 12, 2018; Accepted date: Oct 16, 2018
BACKGROUND: Aminophylline (theophylline) is one of the most frequent asthma therapies in Indonesia, although it remains as a narrow therapy. 
The effects of drugs are individualized and strongly 
influenced by genetic, one of which is  CYP1A2 gene 
polymorphisms. This study aimed to determine the profile 
of CYP1A2 polymorphism and theophylline level in asthma 
exacerbation patients receiving intravenous aminophylline 
therapy.
METHODS: This cross sectional study was conducted in 
the emergency room (ER), to adults asthma exacerbation 
patients without complication (n=27), visiting the ER. The 
gene polymorphism data were compared with theophylline 
levels in the blood using chi-square test.  
RESULTS: In the CYP1A2 gene polymorphism profile, 
the most common heterozygous alleles are T/G genotype 
of CYP1A2*1E and C/A genotype of CYP1A2*1F. Most 
homozygote alleles exist in CYP1A2*1D and CYP1A2*1F. 
There was significant difference between CYP1A2*1D 
(p<0.005), CYP1A2*1E (p<0.023) and CYP1A2*1F 
(p<0.000) polymorphisms and theophylline level.
CONCLUSION: CYP1A2*1D, CYP1A2*1E and 
CYP1A2*1F gene polymorphisms had an effect on 
theophylline levels. However, no one experienced an 
overdose theophylline, and no correlation between 
theophylline levels with CYP1A2 gene polymorphism.
KEywORDS: exacerbation asthma, intravenous 
aminophylline, CYP1A2 polymorphism gene, theophylline 
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Abstract
Introduction
Asthma is a heterogeneous disease and one of the major 
health problems in the world.(1) Asthma is a chronic 
inflammatory disorder of the airways, with many cells and 
cellular elements playing a role.(1,2) Worsening asthma 
symptoms can worsen asthma exacerbation and decrease 
in lung function.(1) Exacerbations of asthma is important 
because it is associated with patient’s quality of life as 
well as substantially increased spending on health system.
(3) Asthma is included in the top 10 non-communicable 
diseases in Indonesia.
 Aminophylline (prodrug of theophylline) is used for 
the treatment of exacerbations of asthma (1), including in 
Indonesia. In Indonesia, aminophylline/theophylline and 
aminophylline are included in the Indonesian National 
Essential  Medicines  List  in  2015  until  now.(4,5) 
Theophylline and aminophylline prices on the market 
tend to be affordable and they are available as over-the-
counter (OTC) that can be used without prescription by 
a doctor, so the effects of drugs cannot be monitored by 
health professionals. Although beta-2 agonist is the first 
line for asthma exacerbations (1), previous studies have 
concluded there is no difference in effectiveness between 
beta-2 agonist and aminophylline. A study on randomized 
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controlled trial published by Travers, et al., said there is 
no consistent evidence for the use of intravenous beta-2 
agonist or intravenous aminophylline for exacerbations 
asthma.(6) Previous research reported that while there 
was no difference in the effectiveness of salbutamol 
(beta-2 agonist) and aminophylline in the first 2 hours, 
aminophylline significantly reduced the length of hospital 
stay.(7) Small doses of theophylline is known to not 
only relax the airway smooth muscle, but also has anti-
inflammatory and immunomodulatory effects, which is the 
basic pharmacology theory for asthma treatment.(8)
 In Indonesia, aminophylline is frequently used as 
primary therapy of asthma exacerbations in the hospital 
because it is effective and rarely causes adverse drug 
reaction (ADR) events even when taken in conjunction 
with other asthma treatment.(9-12) Even when the safety of 
aminophylline compared to salbutamol showed there were 
no significant difference in hypokalemia and hypernatremia 
event.(13) Although the use of theophylline/aminophylline 
has been abandoned, because it is drug with narrow 
therapeutic index and the potential causes of ADR.(14) 
That many studies have proven ADR avent from the use of 
aminophylline in abroad.(15-19)
 Effects of aminophylline can be caused by individual 
characteristics. Genetic factors are the main factors that 
cause different response to asthma therapy (20,21) and drug 
response can be determined by the relationship between 
genotypes (22-25).
 Pharmacogenetic profile in theophylline need to be 
further investigated to describe the pharmacogenetic profile 
Indonesia people associated with metabolism of theophylline 
pharmacokinetics.(26)  Polymorphisms associated with CYP 
(Cytochrome) P450 have been studied previously.(22-25) 
Theophylline is metabolized by CYP450 and CYP1A2 gene 
polymorphism proven to influence theophylline drug levels 
in the blood, on CYP1A2 on CYP1A2*1C, CYP1A2*1D, 
CYP1A2*1E and CYP1A2*1F.(22-25) Previous studies 
have shown Asian subjects tend to be poor metabolism for 
certain drugs and therefore more at risk of adverse events, 
for example Asian subjects have greater drug sensitivity than 
Caucasian in the use of several other drugs, such as warfarin 
(27), propranolol (28) and morfin (29). In Asia in Indonesia, 
previous studies have shown that theophylline is eliminated 
faster than other populations, which require more frequent 
theophylline doses.(30) The most ethnic in Indonesia is 
Java, that most have CYP1A2*1F polymorphism gene.(30) 
A genotype at CYP1A2*1F allele is associated with fast 
metabolism, compared with genotype C. Therefore, the 
A/A genotype of CYP1A2*1F has a faster metabolism than 
C/C or C/A, thus causing lower drug levels.(31) This study 
aimed to determine the profile of CYP1A2 polymorphism 
and theophylline level in blood in asthma exacerbation 
patients receiving intravenous aminophylline therapy.
Methods
Design Research
This was a cross-sectional study. The research variables 
include polymorphism of CYP1A2 gene and theophylline 
level in blood. Subjects received intravenous aminophylline 
therapy, slowly with a slow bolus of 6 mg/kg for 20 
minutes, followed by infusion (0.9% NaCl) at 5 μg/kg/hr. 
Theophylline 1 mg is equivalent to 1:25 mg aminophylline.
(32-34) This study was conducted from January 2014 to 
June 2016.
Subject
The population was all patients with exacerbations of asthma 
with Java race in a hospital in Surabaya. Research subjects 
were all patients with asthma exacerbations in all hospitals 
in Surabaya who meet the inclusion and exclusion criteria 
of the study. The inclusion criteria of the research subjects 
included: (i) patients aged ≥ 18 years; (ii) consent to become 
a subject of research; (iii) the level of mild-moderate 
asthma exacerbations, because at that level corticosteroid 
or other asthma therapies should not be added, and patients 
with severe exacerbations of asthma at a rate of up to life-
threatening need additional therapy such as anticholinergic 
and ccorticosteroids (1) that could affect the study results. 
Exclusion criteria research subjects were: (i) patients who 
use contraception; (ii) the pregnant or lactating patient; 
(iii) patients with chronic renal function impairment; (iv) 
patients with chronic liver disease; (v) patients who smoked 
or quit smoking < 2 years; (vi) patients consuming coffee; 
and (vii) patients admitted to getting asthma exacerbation 
therapy before coming to the emergency room, because 
the other therapy can increase risk of ADR event or drug 
interactions.
 Sampling methods used in the study was consecutive 
sampling since there were no subject frames, only selected 
according to inclusive and exclusion criteria. Subjects which 
was selected were those who came to the hospital dcertain 
period. In this study, the population of unknown size as was 
asthma exacerbations in a hospital in Surabaya. Then  it was 
assumed that the general population was not known, based 
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on the formula of Medical Statistics calculating (35), then 
most minimal research subjects each group in this study was 
26 people. 
CYP1A2 Polymorphism Determination
The polymerase chain reaction-restriction fragment 
length polymorphism (PCR-RFLP) technique was used to 
identify DNA genomic polymorphisms in the 5-flanking 
region and the first intron of the CYP1A2 gene. The steps 
consisted of amplification of determinants of CYP1A2 gene 
polymorphism and RFLP analysis.
 DNA of each subject was extracted using GenElute 
Blood Genomic DNA Kit and used as the PCR reaction 
template. There were 4 PCR reactions that will be carried out 
for each subject, with 4 pairs of primers. PCR reaction was 
carried out in the PCR reaction mixture with GoTaqGreen 
2x Master mix PCR (Promega, ‎Fitchburg, USA) according 
to the product protocol, on PCR (Perkin Elmer, Waltham, 
USA) machine with the following conditions: pre-
denaturation at 95°C for 12 minutes, denaturation at 95°C 
for 1 minute, annealing temperature of 57°C for 1 minute, 
and extension at 72°C for 40 seconds, as many as 40 cycles. 
PCR products were electrophoresed on 3% agarose gel, with 
predictions of each PCR product size as shown in Table 1.
 The PCR products were cut with DdeI, NdeI, StuI, or 
ApaI restriction enzymes, respectively. Polymorphism is 
characterized by whether or not PCR products are cut by 
restriction enzymes as shown in Table 2.
Method of Collecting Data
Examination of theophylline level in blood was done after 
administration of aminophylline therapy for one hour. Five 
mL of blood was taken from the subject by nurse/laboratory 
officer in an ependorf tube. Plasma and serum was separated 
Polymorphic Sites 
at CYP1A2 Primers Primers Position
PCR Product 
Length (bp)
F: 5’- GCT ACA CAT GAT CGA GCT ATA C -3’ -3097 → -3076
R: 5’- CAG GTC TCT TCA CTG TAA TGT TA -3’ -2500 ← -2520
F: 5’- TGA GCC ATG ATT GTG GCA TA -3’ -1589 → -1570
R: 5’- AGG AGT CTT TAA TAT GGA CCC AG -3’ -1423 ← -1445
F: 5’- AAA GAC GGG GAG CCT GGG CTA GGT GTA GGA G -3’ 124 → 154
R: 5’- AGC CAG GGC CAG GGC TGC CCT TGT GCT AAG -3’ 292 ← 263
F: 5’- CCC AGA AGT GGA AAC TGA GA -3’ 613 → 623
R: 5’- GGG TTG AGA TGG AGA CAT TC -3’ 855 ← 836
(G/A) CYP1A2*1C
(t/del) CYP1A2*1D
(T/G) CYP1A2*1E
(C/A) CYP1A2*1F
169
243
598
167
Table 1. Location of polymorphism and length of PCR product, as well as the endonuclease restriction on 
PCR-RFLP.(24)
using centrifugation and kept cool with temperature 2-8°C. 
Theophylline level was measured in a laboratory by using 
chemiluminescent microparticle immunoassay (CMIA) 
method. This study has obtained ethical licenses with 
numbers 01/EC/KERS/2014.
Data Analysis
Genetic examination was carried out at the Purification 
Laboratory and Molecular Biology, Faculty of 
Biotechnology, Universitas Surabaya, which is located 
on  Kalirungkut Tenggilis Highway in Surabaya, which is 
in accordance to the ISO (International Organization for 
Standardization) standard. 
 Once all the data is collected, the gene polymorphism 
data was presented descriptively. The theophylline levels in 
the blood data was observed between different CYP1A2 gene 
polymorphism with a chi-square test to see the relationship 
between them.
Table 2. Determination of the type of product PCR fragment 
for RFLP analysis.
Polymorphic Sites 
at CYP1A2
PCR Product 
Length (bp)
Restriction 
Enzymes Result Allele 
(+) A
(-) G
(+) T
(-) del
(+) G
(-) T
(+) C
(-) A
(G/A) CYP1A2*1C
(t/del) CYP1A2*1D
(T/G) CYP1A2*1E
(C/A) CYP1A2*1F
169 Stu I
243 Apa I
598 Dde I
167 Nde I
(+): can be cut with restriction enzymes; (-): cannot be cut with 
restriction enzymes.
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n (%)
Female 14 51.85
Male 13 48.15
Late adolescence (17-25) 5 18.52
Early adult (26-35) 5 18.52
Late adult (36-45) 7 25.93
Early elderly  (46-55) 8 29.63
Late elderly (56-65) 2 7.41
Average 40.11
Household assistant 10 37.04
Entrepreneur 9 33.34
Employee 4 14.81
Student 4 14.81
Employment
Intravenous Aminophylline
Group (n=27)Characters Baseline
Gender
Age (years)
Table 3. Characteristic of subjects using aminophylline 
intravenous and nebulized salbutamol group.
The study was involving 27 research subjects and the 
description of subjects can be seen in Table 3. None of the 
study subjects have an accompanying disease. 
Frequency Distribution of CYP1A2 Gene Polymorphism
It  was  known  that  most  heterozygous alleles are T/G 
genotypes of CYP1A2*1E (81.48%) and C/A genotype of 
CYP1A2*1F (77.78%), whereas most homozygous alleles 
belong to study subjects were G/G genotype of CYP1A2*1C 
(85.19%) and T/T genotype of CYP1A2*1D (70.37%). 
In the profile of CYP1A2 polymorphism gene was found 
mutant genotype, which was in CYP1A2*1C. Meanwhile, 
in CYP1A2*1E polymorphism was not found any G/G 
genotype (Table 4).
Theophylline Content Profile after Intravenous 
Aminophylline for 1 Hour
Theophylline levels in the blood in all study subjects who 
received intravenous aminophylline therapy did not have 
overdose, and most were in the normal range. The normal 
level of theophylline therapy in the blood is 10-15 mg/L 
(56-83 μmol/L). although improvement in lung function 
can be observed at 5 mg/L concentration (28 mmol/L) while 
toxicity increases at > 20 mg/L. All of the study subjects did 
p-value> 0.05, means there is no difference between the two 
groups.
n %
G/G Wild-type 23 85.19
G/A Heterozygous 3 11.11
A/A Homozygous 1 3.70
T/T Wild-type 19 70.37
T/del Heterozygous 0 0
del/del HomozygousMutans 8 29.63
T/T Wild-type 5 18.52
T/G Heterozygous 22 81.48
G/G Homozygous 0 0
C/C Wild-type 0 0
C/A Heterozygous 21 77.78
A/A Homozygous 6 22.22
CYP1A2*1C 
(-2964 G＞A)
CYP1A2*1D 
(-1569 delT)
CYP1A2*1E 
(-155 T＞G)
Total (n=27)
CYP1A2*1F 
(-731 C＞ A)
CYP1A2  Genetic 
Polymorphism Genotype Phenotype
Table 4. Frequency distribution of CYP1A2 gene 
polymorphisms on intravenous aminophyllline.
Discussion
not show theophylline levels above the therapeutic range 
(toxicity). There were even 3 people who showed levels 
of theophylline below the range of therapy but all of them 
showed improvement of the symptoms of asthma.(36)
 The description between blood drug levels and 
CYP1A2 gene polymorphisms in the study subjects 
receiving intravenous aminophylline therapy can be seen 
in Table 5 and Table 6. In Table 5, the three subjects who 
had theophylline levels below the normal range (< 10 μg/
mL) had del/del (mutant) allele of CYP1A2*1D and A/A 
genotype (homozygous) of CYP1A2*1F. The CYP1A2*1D 
gene polymorphism causes increased theophylline 
levels and the gene polymorphism in CYP1A2*1F 
causes a decrease in theophylline level. Table 4 shows 
the relationship between blood theophylline levels and 
CYP1A2 gene polymorphism in CYP1A2*1D, CYP1A2*1E 
and CYP1A2*1F polymorphisms. Although there was a 
correlation between theophylline levels in the blood and 
the three polymorphisms, it is not yet possible to conclude 
which polymorphism was most influential on theophylline 
metabolism because the data retrieval was done only once 
and it did not illustrate the elimination of theophylline.
The results of the study showed the effect of CYP1A2 
genetic polymorphism in Indonesians. Although both 
are Asian races. these results are different from those 
conducted in Japan. According to Obase, et al., in the 
Results
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population of asthma patients in Japan CYP1A2*1C.(24) 
The CYP1A2*1D, CYP1A2*1E and CYP1A2*1F were 
found. Another study in patients with lung cancer in Japan 
also found the four CYP1A2 polymorphic alleles.(37) A 
preliminary study of CYP1A2*1F polymorphism profiles in 
Java tribes in Indonesia showed that the frequency of the 
CYP1A2*1F gene in Indonesian population is greater than 
that of the population in Egypt, Japan and the UK, but lower 
than that of Malaysia.(30)
 Profile of CYP1A2 allele effect on metabolism based 
on literature, includes CYP1A2*1C, CYP1A2*1D and 
CYP1A2*1F. The CYP1A2*1C has been shown to affect 
Genotype Types of allele pairs Genotype
Types of 
allele pairs Genotype
Types of 
allele pairs Genotype
Types of 
allele pairs
4.88 below the normal range G/G W del/del M T/G H A/A M
6.3 below the normal range G/G W del/del M T/T W A/A M
10.94 in the normal range G/G W del/del M T/G H C/A H
10.4 in the normal range G/A H del/del M T/T W A/A M
9.19 below the normal range G/A H del/del M T/T W A/A M
10.26 in the normal range G/A H del/del M T/T W A/A M
14.29 in the normal range G/G W T/T W T/G H C/A H
12.5 in the normal range A/A M del/del M T/T W A/A M
10.5 in the normal range G/G W del/del M T/G H C/A H
12 in the normal range G/G W T/T W T/G H C/A H
10.2 in the normal range G/G W T/T W T/G H C/A H
13.2 in the normal range G/G W T/T W T/G H C/A H
11.9 in the normal range G/G W T/T W T/G H C/A H
10.4 in the normal range G/G W T/T W T/G H C/A H
15.1 in the normal range G/G W T/T W T/G H C/A H
13.3 in the normal range G/G W T/T W T/G H C/A H
12.86 in the normal range G/G W T/T W T/G H C/A H
12.59 in the normal range G/G W T/T W T/G H C/A H
15.02 in the normal range G/G W T/T W T/G H C/A H
14.37 in the normal range G/G W T/T W T/G H C/A H
13.55 in the normal range G/G W T/T W T/G H C/A H
12.71 in the normal range G/G W T/T W T/G H C/A H
13.52 in the normal range G/G W T/T W T/G H C/A H
14.2 in the normal range G/G W T/T W T/G H C/A H
17.1 in the normal range G/G W T/T W T/G H C/A H
13.2 in the normal range G/G W T/T W T/G H C/A H
12.6 in the normal range G/G W T/T W T/G H C/A H
Theophylline Levels in Blood 
(μg/mL)
CYP1A2*1C CYP1A2*1D CYP1A2*1E CYP1A2*1F
Table 5. Profile of theophylline in blood after administration of aminophylline for 1 hour with genetic polymorphism on all 
subjects receiving intravenous aminophylline therapy.
The normal range of blood theophylline levels is 10-20 μg/mL. Allele pair type: W = wild; H = heterozygous; M = homozygous/mutants.
theophylline metabolism in Japanese patients with asthma. 
Theophylline clearance decreased significantly in asthma 
patients who had G/A or A/A genotype of CYP1A2*1C 
compared to the G/G genotype. It has also been reported 
that high theophylline clearance values were significantly 
correlated with age in the G/G genotype.(24) The T allele 
of the CYP1A2*1D (T/T or T/del) was associated with 
a decrease in the theophylline metabolism associated 
with increased CYP1A2 activity compared to the del/
del genotype, which means that gene polymorphisms in 
CYP1A2*1D alleles increase theophylline metabolism 
which causes increased theophylline levels in blood.(23) A 
68
The Indonesian Biomedical Journal, Vol.11, No.1, April 2019, p.63-9 Print ISSN: 2085-3297, Online ISSN: 2355-9179
allele of the CYP1A2*1F is a faster metabolizer compared 
to C allele. Therefore, the A/A genotype of CYP1A2*1F has 
a faster metabolism than C/C or C/A, leading to lower drug 
levels.(31) Theophylline is metabolized in the liver using 
the P450 cytokrom enzyme and its metabolism is affected 
by the CYP1A2 enzyme. 
 This study has some limitations,  first one is the types 
of asthma phenotype. According to Asthma Management 
Handbook there is a strong association between asthma 
and allergies. and over 80% of asthmatics have allergic 
sensitivities. These allergies trigger the onset of asthma 
exacerbations. So patients should avoid allergic exposure to 
keep their asthma under control because there is a strong 
association between asthma and allergies that is more than 
80% of asthmatics have allergic sensitivity.(32) The effect of 
asthma type will be need to be discussed with the response 
to corticosteroid therapy. In allergy types, asthma provides 
a better response to corticosteroid therapy than non-allergic 
asthma.(1) However, since all subjects did not use additional 
corticosteroid therapy, so the type of asthma did not affect 
the results of the study. The second limitation is the race 
of participant. The research subjects were of mixture of 
different ethnic, and it was hard to correspond the genetic 
polymorphism found in this study to any specific ethnic/
Conclusion
In this study, the most heterozygous genotypes found were 
the T/G genotype of CYP1A2*1E and the C/A genotype 
of CYP1A2*1F, whereas the most homozygous genotype 
was the G/G genotype of CYP1A2*1C and T/T genotype 
of CYP1A2*1C. Most  homozygoues  alleles  exist  in 
CYP1A2*1D in the form of del/del genotipe and CYP1A2*1F 
in the form of A/A allele. Meanwhile in polymorphism 
CYP1A2*1E no homozygous allele (G/G) was found. There 
was a relationship between blood theophylline levels and 
CYP1A2 gene polymorphism in CYP1A2*1D, CYP1A2*1E 
and CYP1A2*1F polymorphisms. Identification of CYP1A2 
gene polymorphism can support asthma treatment in 
predicting  theophylline therapeutic  effect  so  as  to  prevent 
adverse  drug  reactions  and  appropriate  dose  adjustments.
Allelel (Genotype) G/G (W) G/A (H) A/A (M) Total del/del (M) T/T (W) Total
Underdose 2 1 0 3 3 0 3
Normal 21 2 1 24 5 19 24
Overdose 0 0 0 0 0 0 0
Total 23 3 1 27 8 19 27
The mean blood levels of 
theophylline (μg/mL)
12.38 9.95 12.5 9.37 13.27
Theophylline Levels 
in Blood
0.415 0.005*
n
p -value
n
p -value
CYP1A2*1C Gene Polymorphism CYP1A2*1D Gene Polymorphism
Allelel (Genotype) T/G (H) T/T (W) Total C/A (H) A/A(M) Total
Underdose 1 2 3 0 3 3
Normal 21 3 24 21 3 24
Overdose 0 0 0 0 0 0
Total 22 5 27 21 6 27
The mean blood levels of 
theophylline (μg/mL) 12.66 9.73 13.03 8.92
0.000*
Theophylline Levels 
in Blood
p -value
0.023*
n
p -value
n
CYP1A2*1E Gene Polymorphism CYP1A2*1F Gene Polymorphism
Table 6. Cross-tabulation of CYP1A2 polymorphisms with theophylline levels in blood on sample research getting intravenous 
aminophylline intervention.
The normal range of blood theophylline levels is 10-20 μg/mL. Allele pair type: W = wild; H = heterozygous; M = 
homozygous/mutants. p-value was obtained by chi-square test, *significant difference to theophyline levels.
race. And the last one is the long observation of theophylline 
level in blood. Examination of theophylline level in blood 
was done only once. one hour after aminophylline therapy. 
Therefore it was not known how large was the influence of 
CYP1A2 gene polymorphism on metabolism and profile of 
theophylline excretion in blood.
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